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SulTlmal-y 
30 years ago, investigations into the molecular basis of the delayed-type hypersensitivity reac- 
tion (DTH) provided evidence for the first lymphokine activity: a lymphocyte-derived media- 
tor called macrophage migration inhibitory factor (MIF), which inhibited the random migra- 
tion of peritoneal macrophages. Despite the long-standing association of MIF with the DTH 
reaction and the cloning of a human protein with macrophage migration inhibitory activity, 
the precise role of MIF in this classic cell-mediated immune response has remained undefined. 
This situation has been further complicated by the fact that two other cytokines, interferon y 
and IL-4, similarly inhibit macrophage migration and by the identification of mitogenic con- 
taminants  in some preparations of cloned human  MIF.  Using recently developed molecular 
probes for mouse MIF, we have examined the role of this protein in a classical model of DTH, 
the tuberculin reaction in mice. Both MIF messenger 1KNA and protein were expressed prom- 
inently in DTH lesions, as assessed by reverse transcription polymerase chain reaction, in situ 
hybridization, and immunostaining with anti-MIF antibody. The predominant cellular origin 
of MIF appeared to be the monocyte/macrophage, a cell type identified recently to be a major 
source of MIF release in vivo. The administration of neutralizing anti-MIF antibodies to mice 
inhibited significantly the development of DTH, thus affirming the central role of MIF in this 
classic immunological response. 
C 
ell-mediated immunity is the principle host response 
to a variety of viral, bacterial, and parasitic infections, 
and it plays  a critical role in controlling invasion by intra- 
cellular pathogens such as Mycobacterium  tuberculosis (1). The 
delayed-type  hypersensitivity  reaction  (DTH)  exhibits 
many features of this response and is characterized histolog- 
ically by the infiltration and accumulation of mononuclear 
cells  (i.e., macrophages and T  cells)  into regions of infec- 
tion or antigen deposition. DTH is readily demonstrated by 
the classic tuberculin reaction in which the intradermal in- 
jection of mycobacterial purified protein derivative (PPD) 
into previously sensitized hosts produces erythema and in- 
duration that persists for 24-72 h  (2). Thirty years ago, in- 
vestigations into the molecular basis of DTH provided evi- 
dence  for the  first  lymphokine  or  cytokine  "activity," a 
nondialyzable substance present in lymphoid cell superna- 
tants that inhibited the random migration of peritoneal ex- 
udate cells (3, 4). A protein designated macrophage migra- 
tion inhibitory factor (MIF)  was  proposed to account for 
this activity and was ultimately cloned from a human T  cell 
line in 1989 (5). 
Numerous studies over the years have implicated various 
T cell- and macrophage-derived cytokines in the induction 
of the DTH response (6-9). Yet, despite the long-standing 
association of MIF "activity" with the DTH reaction, the 
precise role of the MIF "protein" in this immunological re- 
sponse  has  remained  undefined.  This  situation  has  been 
further confounded by the description of two other cyto- 
kines:  IFN-~/  and  IL-4,  which  exhibit MIF  activity (10, 
11),  and by the  unavailability both of purified, mitogen- 
free MIF protein and of specific, neutralizing anti-MIF an- 
tibodies (12,  13). In a series of recent studies, however, the 
mouse  homologue  of  human  MIF  has  been  isolated, 
cloned, and identified to be a major secretory product of 
anterior pituitary cells and activated macrophages (14,  15). 
The mouse and human MIF proteins also  have been ex- 
pressed in high yield, purified, and have become available 
for  biological  studies  (16).  MIF,  for  example,  has  been 
found to potentiate endotoxin (LPS) lethality and neutral- 
izing anti-MIF antibodies fully protect mice in experimen- 
tally-induced septic shock  (14).  MIF induces the produc- 
tion of TNF-ci and acts  together with IFN-y to promote 
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recently to  be released  from  immune  cells by glucocorti- 
coid stimulation and, once secreted,  acts to counterregulate 
glucocorticoid inhibition ofcytokine production (17). 
In the present study, we used recently developed molec- 
ular probes  for  mouse  MIF  to  reexamine  the  role  of this 
protein in a  classical model of DTH,  the  tuberculin reac- 
tion. Both MIF protein and RNA  were expressed in DTH 
lesions and were localized predominantly to cells of the mono- 
cyte/macrophage lineage.  The  administration of neutraliz- 
ing anti-MIF antibodies to  previously sensitized mice  in- 
hibited  significantly the  development  of DTH,  affirming 
the  central  role  of MIF  in  this  classic  immunological re- 
sponse. 
Materials  and Methods 
Reagents.  CFA containing 1 mg/ml M.  tuberculosis H37Ra was 
obtained from Sigma Chemical Co. (St, Louis, MO). Tuberculin 
purified protein derivative (PPD) used for in vivo immunizations 
was from Cooper's Animal Health Inc. (Kansas City, KS). Tuber- 
sol  |  tuberculin purified protein derivative (Connaught Laborato- 
ries  Ltd.,  Toronto,  Canada)  was  used for the  in vitro  cytokine 
production assays and was dissolved in sterile PBS (final concen- 
tration of 1 mg/m])  and stored at 4~  The PPD solution con- 
tained negligible quantities of endotoxin (10.6 pg LPS/Ixg PPD) 
as determined by the  Limulus amoebocyte  assay  (BioWhittaker, 
Inc., Walkersville, MD). 
Induction and Quantitation of the DTH Response.  Female BALB/c 
mice (n =  5-6 per group) were primed by subcutaneously inject- 
ing 25 I*1 of CFA into the plantar aspect of a distal hind paw and 
50  txl of CFA into the dorsal aspect of the neck.  12 d later, the 
mice were injected with 25 txl of PPD into the contralateral hind 
paw. Control animals received an injection ofpyrogen-free saline 
instead of the PPD challenge. After 48 h, the mice were killed by 
CO2 asphyxiation and the hind paws were examined for footpad 
swelling before histological and RNA expression studies. 
Footpad thickness was measured in a blinded fashion with an 
electronic caliper (code 500-133; Mitutoyo Corporation, Tokyo, 
Japan) both before and 48 h  after PPD  challenge (18,  19).  The 
precision of this caliper was  +5 Ixm. Each thickness measurement 
was obtained in triplicate for each animal and time point, and care 
was taken to avoid exerting tension upon the skin and compress- 
ing edema fluid (20).  Values  are  expressed  as the  difference in 
footpad thickness for each mouse measured before and after chal- 
lenge (Athic k .....  [Ixm]). 
A  polyclonal rabbit antiserum raised to  purified, recombinant 
mouse MIF was used for the antibody neutralization studies and 
was established previously to neutralize MIF activity in vivo (14). 
For antibody inhibition of DTH, 200 txl of polyclonal rabbit anti- 
mouse MIF serum or control, normal rabbit serum (NKS), was 
injected intraperitoneally 2 h before injecting 50 p,1 of a 1:1 mix- 
ture  of PPD  and either anti-MIF serum or NRS  into the  con- 
tralateral  hind paw of the previously sensitized mice. 12 mice were 
studied per group and footpad swelling was assessed and quanti- 
tated as described above.  For histological studies, the  distal  hind 
limbs were detached mid-tibiotarsally immediately after euthanasia 
and fixed in 10%  neutral-buffered formalin for 48 h.  The tissues 
were decalcified, embedded in paraffin, and 0.5-0.6-fxm sections 
cut through the mid-longitudinal  section of each specimen (21). 
Reverse Transcription PCR  (RT-PCR)  Analysis.  DTH  reac- 
tions were induced in mice (n =  4 per group) as described above 
and the footpads removed and rapidly transferred into a solution 
of RNAzol-B  (Tel-Test Inc., Friendswood, TX)  for RNA ex- 
traction.  RT-PCR  for MIF was  performed as  described previ- 
ously (15),  except that the annealing step was performed at 60~ 
and the DNA amplification reactions were cycled 26 times. The 
intron spanmng mouse MIF primers were 5'-CCATGCCTATGT- 
TCATCGTG-3' and 5'-GAACAGCGGTGCAGGTAAGTG-3' 
and  the  [3-actin  primers  were  5'-GTGGGCCGCTCTAGG- 
CACCA-3' and 5'-TGGCCTTAGGGTTCAGGGGG-3'. 
In Situ Hybridization Studies.  BALB/c mice (n =  2) were im- 
munized with  CFA as  described above  and  12  d  later injected 
subcutaneously with  30  txl  of PPD  into  the  contralateral hind 
paw. The in situ hybridization procedures followed methods de- 
scribed previously and were performed on paraffin-embedded tis- 
sue sections that were subjected to limited proteinase K digestion 
(21,  22).  The  MIF mRNA-specific probe  was  obtained as fol- 
lows. The plasmid pETllb (Novagen, Madison, WI) containing 
the full-length mouse MIF cDNA (16) was digested with the re- 
striction enzymes XbaI  and BamHI,  and the  348-bp insert was 
isolated  and  ligated  into  the  XbaI/BamHI-digested  phagemid 
Bluescript  SK  +  (Stratagene,  La Jolla,  CA).  The  antisense ribo- 
probe  was  obtained by linearizing the  resulting construct with 
BamHI and synthesizing the complementary RNA from the T3 
promoter using an RNA synthesis kit (Promega, Madison, WI). 
The  sense riboprobe was  obtained by linearizing the  phagemid 
construct with XbaI and using the T7 promoter for RNA syn- 
thesis.  Serial sections  also  were  stained for  macrophage/mono- 
cyte-specific  (Ramll  mAb  [diluted  1:30]; DAKO,  Carpinteria, 
CA) and T  cell-specific (anti-Thy-1.2 mAb [diluted 1:10]; Boeh- 
ringer  Mannheim Biochemicals,  Indianapolis,  IN)  cell  surface 
markers (23). 
Immunohistochemical Analysis of MIF Protein.  Control or DTH 
footpads  were  obtained from  two  mice per group  as  described 
above,  immersed  in  OCT  embedding  medium  (Tissue-Tek; 
Miles Inc., West Haven, CT), and snap frozen in isopentane/liq- 
uid N 2.  5-p.m frozen sections then were cut and placed on poly- 
L-lysine--coated slides. Immunohistochemical staining of MIF was 
performed following a modification of the avidin-biotin complex- 
immunostaining  procedure (23),  except that the slides were incu- 
bated with the primary antibody for  16  h  at  4~  Rabbit anti- 
MIF serum and N1KS were used at a dilution of 1:500. Negative 
staining controls used PBS or NRS  instead of the primary anti- 
body  solution.  In  separate  experiments,  preincubation of anti- 
MIF antiserum with recombinant MIF was found to abolish posi- 
tive immunostaining. 
Analysis  of PPD-induced Cytokine  Production.  Cytokine  pro- 
duction was analyzed in cell culture supernatants of RAW 264.7 
mouse macrophages, thioglycollate-elicited mouse peritoneal ex- 
udate cells  (PECs), and purified mouse T  cells. T  cells were pre- 
pared  from  the  spleens  of unprimed BALB/c  mice  by passage 
over a mouse T  cell enrichment column (R&D Systems, Minne- 
apolis, MN) and were >95% pure by flow cytometry analysis af- 
ter staining with an anti-CD3 antibody (PharMingen, San Diego, 
CA). Macrophages  (3  ￿  106 cells/ml) or T  cells  (2  ￿  106 cells/ 
ml)  were  cultured in RPMI  1640/10%  FBS  containing 2  mM 
glutamine and 50  Izg/ml gentamicin (GIBCO  BRL,  Gaithers- 
burg, MD) and were incubated for 16 h with various concentra- 
tions  of PPD  (10  pg/ml-10  ~g/ml).  Cell-conditioned media 
were removed at intervals, and the MIF content was analyzed by 
SDS-PAGE/Westem blotting (15)  and ELISA  (Metz,  C.  N., J. 
Bernhagen, M.  Bacher,  T.  Calandra,  S.  B.  Doty,  T.  Donnelly, 
and R.  B.  Bucala, manuscript in preparation). Western blotting 
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bination with enhanced chemiluminescence (Amersham Life Sci- 
ences, Arlington Heights, IL). TNF-~x activity was quantitated by 
L929 cell cytotoxicity (15). 
Results 
The  injection  of PPD  into  the  footpads of CFA-sensi- 
tized mice produced within 48  h  a  characteristic DTH  re- 
sponse:  erythema,  induration,  and  mononuclear  cell infil- 
tration. Evidence for the expression of MIF in this response 
was first obtained by RT-PCR  analysis. Total tissue RNA 
was prepared from four PPD-injected and four saline-(con- 
trol) injected footpads, reverse transcribed, and the  result- 
ing cDNA  products  were  amplified with  intron-spanning 
MIF or [3-actin primers. DNA  amplification for 26  cycles 
demonstrated prominent MIF expression in the DTH,  but 
not in the control mouse footpads (Fig. 1). 
To  assess  the  importance  of MIF  production  in  this 
model of the DTH  response, we then treated CFA-primed 
mice (n =  6 per group) with either a neutralizing antiserum 
raised  to  recombinant  mouse  MIF  or  a  control  (nonim- 
mune)  serum. After PPD  challenge, mice that were treated 
with  anti-MIF  antiserum  showed  a  significantly reduced 
footpad inflammatory reaction at 48  h  when  compared to 
mice treated with control serum.  The mean footpad thick- 
ness  (Athickness) was  170  -  20  p~m in the  anti-MIF-treated 
mice  versus  240  --  30  p,m  in  the  control mice  (mean  - 
SEM,  P  <0.05,  by Student's t test, independent variable). 
Histological  examination  showed  a  mixed  mononuclear 
cell  infiltrate,  a  few  scattered  neutrophils,  and  dermal 
edema in both groups of footpads. However, the degree of 
infiltration and  dermal expansion was  approximately two- 
fold less in  the  anti-MIF-treated mice than  in  the  control 
serum-treated group  (Fig. 2). There was also a marked de- 
gree of vascular dilatation in the control DTH  lesions that 
was  not  present  in  the  footpads  of the  anti-MIF-treated 
mice. 
Figure 1.  RT-PCR analysis  of MIF expression in the tuberculin DTH 
reaction. RNA was isolated from the footpads ofCFA-sensitized BALB/c 
mice 48 h after injection of PPD or saline (n =  4 mice per group). The 
DNA amplification products shown were obtained from a representative 
PPD-injected  (DTH),  and a normal saline-injected (N) footpad. CON, 
PCR control performed without added cDNA template. STDs, DNA bp 
standards. 
Although  MIF  activity has  been  historically considered 
to  be  a  product  of activated T  cells  (3,  4),  recent  studies 
have identified the macrophage to be an important source 
of MIF  production  in  vivo  (15).  To  investigate  the  cell 
source(s) of MIF production in the DTH  response, we per- 
formed in  situ hybridization analysis of MIF gene  expres- 
sion  in  DTH  lesions  obtained  from  the  PPD-injected, 
CFA-sensitized  mice.  Cells  that  were  positive  for  MIF 
mRNA  expression were  identified to  be  present in  tissue 
sections  that  were  hybridized to  an  MIF  antisense  probe 
(Fig. 3 A), but not in tissue sections that were hybridized to 
an  MIF  sense  probe  (Fig.  3  B).  The  cells  that  expressed 
MIF were grouped in clusters and appeared overall to dis- 
play a  morphology that  was  more  consistent with  that  of 
monocytes/macrophages  (i.e.,  abundant  cytoplasm  and  a 
large  round  or  oval  nucleus)  than  with  T  lymphocytes. 
This  impression was  confirmed by costaining studies per- 
formed  with  antibodies  directed  against  the  monocyte/ 
macrophage-specific  marker  Ram11  and  the  T  cell-spe- 
cific marker Thy-l.2. The Ram11-positive cells were clus- 
tered and  colocalized with  the  MIF mRNA-positive cells 
279  Bernhagen et al.  Brief  Definitive Report 
Figure 2.  Effect  ofanti-MIF anti- 
serum  on  DTH.  Representative 
footpad sections from  an  anti-MIF 
serum-treated mouse (Anti-MIF) and 
from a control NRS-treated  mouse 
(NRS).  X 150.  Arrows  indicate 
blood vessels. Figure  3.  In situ hybridization of MIF mkNA in 
DTH. Footpads of CFA-sensitized BALB/c mice were 
injected with PPD 48 h before analysis by in situ hy- 
bridization with MIF-specific antisense (A) and sense 
(B) riboprobes. Cell types were determined by immuno- 
staining serial sections for  the  macrophage-specific 
marker P.am11  (C)  and  the  T  cell-specific marker 
Thy-l.2  (E), Antibody specificity was established by 
staining studies performed in the absence of the respec- 
tive primary antibodies (D and F). ￿  300. 
(Fig.  3,  C  and  D),  whereas  the  Thy-l.2-positive  T  cells 
were distributed in a more diffuse and homogenous pattern 
(Fig.  3,  E  and  iV). The  Thy-l.2  positive  cells  displayed  a 
morphology  that  was  smaller  and  more  round  than  the 
1Lamll-positive  monocytes/macrophages.  Immunohisto- 
chemical staining of DTH footpads with anti-MIF antibody 
also  showed the  MIF-positive  cells  to  be  more  consistent 
morphologically  with  cells  of the  monocyte/macrophage 
phenotype (Fig. 4). 
The  role of the  macrophage  in  the  DTH  response  was 
investigated further by examining the ability of PPD to di- 
rectly  induce  MIF  production  in  vitro.  PPD,  a  protein- 
enriched  fraction  of M.  tuberculosis culture  filtrate,  is  a 
known macrophage activator that has been reported to di- 
rectly induce  the  release  of a  number  of proinflammatory 
mediators  such  as TNF-er  and  IL-1  (24-26).  Supernatants 
obtained  from  PPD-stimulated  (100  pg/ml-10  txg/ml) 
RAW  264.7  mouse  macrophages  were  found  to  contain 
significant quantities of TNF-oL, as measured by L929 cyto- 
toxicity  (0.02  ng/ml-10.4  ng/ml),  thereby  confirming 
these previous observations  (data not shown).  Of note, in- 
cubation  of RAW  264.7  mouse  macrophages  with  PPD 
(100  pg/ml-10  p,g/ml)  for  16  h  also  produced a  specific, 
concentration-dependent  release  of MIF that was detected 
by  SDS-PAGE/Western  blotting  (Fig.  5  A).  By  ELISA 
Figure  4.  Irnmunohistochemical  staining of representative DTH le- 
sions with anti-MIF antibody (￿  Control studies performed with 
NP.S or PBS in place of the primary antibody solution were uniformly 
negative (not shown). 
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PECs (B). Macrophages were incubated for 16 h with PPD at the indi- 
cated concentrations, and the MIF secreted into the medium were ana- 
lyzed by Western blotting. 10 rig of rMIF was electrophoresed and trans- 
ferred as a standard. ST, molecular  weight markers. 
analysis, the MIF-positive supernatants were determined to 
contain immunoreactive MIF that was in the range of 1.8- 
7.4  ng/ml.  A  similar  PPD-induced  secretion  of MIF  was 
observed in thioglycollate-elicited,  peritoneal  macrophages 
(Fig.  5  B),  although  ELISA  analysis  showed  that  lower 
amounts  of MIF  were  produced  by  these  primary  mac- 
rophages  (0.05-0.2  -+  0.1  ng/ml;  mean  _+  SD of four ex- 
periments).  By contrast, MIF release was not detected after 
stimulation  of primary mouse T  cells or the LB1KM T  cell 
line with PPD  (100 pg/ml-10  txg/ml for 16 h),  as assessed 
by  SDS-PAGE/Western  blotting  using  a  sensitive  en- 
hanced  chemiluminescence  staining  method  or  by  MIF- 
specific ELISA analysis (not shown). 
Discussion 
The  tuberculin  skin  reaction  is  a  classical  model  of the 
DTH  response.  It is  specific  to  the  sensitizing  stimulus,  is 
"delayed" in onset, and is mediated strictly by a cellular ira- 
mune  response  and  not  by  humoral  antibodies.  That  the 
administration of neutralizing anti-MIF antibodies to sensi- 
tized  mice  inhibits  the  development  of DTH  affirms  the 
many  observations  over  the  years  that  have  linked  MIF 
"activity"  with  soluble  product(s)  elaborated  by the  infil- 
trating mononuclear cells  (3,  4). While MIF has been con- 
sidered originally to be a product of activated T  ceils (3,  4), 
however,  the  present  data  indicate  that  the  macrophage, 
rather  than  the  T  cell,  is  the  predominant  source  of the 
MIF  expressed  in  the  tuberculin-induced  DTH  reaction. 
The macrophage has been shown recently to be responsible 
for much of the MIF which is produced in vivo (15).  MIF 
is present in preformed intracellular stores and is readily re- 
leased from macrophages by stimulation with  Gram-nega- 
tive endotoxin,  Gram-positive exotoxins,  or by the proin- 
flammatory  cytokines  TNF-0t  and  IFN-y  (15,  Calandra, 
T., unpublished observations). 
Although the present data indicate that PPD can directly 
elicit  MIF production  from macrophages,  the  precise  sig- 
nals necessary to induce the production of MIF from mac- 
rophages in vivo may vary with the nature of the particular 
invasive stimulus.  Thus,  in the absence of microbial prod- 
ucts such as PPD, the macrophage release of MIF in DTH 
may  be  induced  by  IFN-"/  secreted  from  antigen-stimu- 
lated  T  cells  and/or  by  TNF-e~  released  in  an  autocrine 
fashion  from  infiltrating  monocytes/macrophages.  While 
MIF expression was not detected in T  cells by either in situ 
hybridization  or immunostaining,  the present  data  do  not 
exclude  a  role  for  T  cell  MIF  in  the  elaboration  of the 
DTH  response.  Like  the  macrophage,  T  cells  have  been 
identified recently to contain MIF protein in preformed in- 
tracellular pools (15).  MIF can be released  from T  ceils  by 
both  mitogen-  and  antigen-specific  stimuli,  and  T  cell- 
derived MIF also may contribute significantly to the evolu- 
tion of the DTH response. 
Macrophage  and  T  cell  MIF  is  secreted  in  direct  re- 
sponse to glucocorticoid stimulation and acts to "override" 
the  inhibitory  effect of steroids  on proinflammatory  cyto- 
kine production (i.e.,  TNF-0t, IL-113,  IL-6, and IL-8) (17). 
Locally produced MIF thus may act to balance the antiin- 
flammatory effects of stress- or infection-related increases in 
systemic  glucocorticoids  that  might  prevent  local  inflam- 
matory responses  from working to eliminate  the source of 
tissue invasion. 
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